Item 8.01 Other Events. As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “ Company ”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231 s…
Filed Nov 20, 2026Accepted Nov 20, 2026, 4:06 PM ESTCIK 1433607Accession 0001493152-26-053487
InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
As
previously disclosed, on November 16, 2026, InspireMD, Inc. (the “ Company ”) closed its previously announced offering
of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), and
pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231
shares of Common Stock (the “ Common Warrants ”), pursuant to the Company’s effective automatic shelf registration
statement on Form S-3 (File No. 333-286309) previously filed with the Securities and Exchange Commission (the “ SEC ”),
raising approximately $34.9 million in net proceeds after deducting underwriting discounts and before offering expenses. Pursuant to
the Underwriting Agreement, dated November 13, 2026 (the “ Underwriting Agreement ”), by and among the Company and Lake
Street Capital Markets, LLC, as representative (the “ Representative ”) of the several underwriters named therein (collectively,
the “ Underwriters ”), the Underwriters were granted a 30-day option (the “ Option ”) to purchase up
to an additional 8,635,846 shares of Common Stock (the “ Option Shares ”) and/or Common Warrants to purchase up to 6,490,384
shares of Common Stock (the “ Option Common Warrants ”) from the Company on the same terms and conditions.
On
November 18, 2026, the Representative notified the Company that it had elected to exercise the Option in full. The offering of the Option
Shares and Option Common Warrants closed on November 20, 2026, raising an additional approximately $5.3 million in net proceeds after
deducting underwriting discounts and before offering expenses.
The Option Common Warrants
will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026, by and between the Company and Securities Transfer
Corporation, as warrant agent.